Shenzhen Neptunus Bioengineering Co., Ltd.

Shenzhen Stock Exchange 000078.SZ

Shenzhen Neptunus Bioengineering Co., Ltd. Current Liabilities for the year ending December 31, 2023: USD 3.91 B

Shenzhen Neptunus Bioengineering Co., Ltd. Current Liabilities is USD 3.91 B for the year ending December 31, 2023, a -9.24% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Shenzhen Neptunus Bioengineering Co., Ltd. Current Liabilities for the year ending December 31, 2022 was USD 4.30 B, a -8.13% change year over year.
Shenzhen Neptunus Bioengineering Co., Ltd. Current Liabilities for the year ending December 31, 2021 was USD 4.68 B, a -4.07% change year over year.
Shenzhen Neptunus Bioengineering Co., Ltd. Current Liabilities for the year ending December 31, 2020 was USD 4.88 B, a 6.83% change year over year.
Shenzhen Neptunus Bioengineering Co., Ltd. Current Liabilities for the year ending December 31, 2019 was USD 4.57 B, a 2.90% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Shenzhen Stock Exchange: 000078.SZ

Shenzhen Neptunus Bioengineering Co., Ltd.

CEO	Mr. Feng Zhang
IPO Date	Dec. 18, 1998
Location	China
Headquarters	Wang Yinhe Technology Building
Employees	9,093
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Shenzhen Neptunus Bioengineering Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products primarily in China. It offers drugs in the fields of anti-tumor, cardio-cerebrovascular, marine drugs, and other fields. The company was founded in 1989 and is based in Shenzhen, China.

Key trends

Past 5 years